Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Commentary: targeting myelodysplastic syndromes

Carlos M de Castro¹

¹Division of Medical Oncology, Duke University Medical Center, Box 3872, Durham, NC 27710, USA .

Leukemia Research

|August 23, 2002

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

The Lancet. Haematology·2025

Same author

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.

Expert opinion on pharmacotherapy·2024

Same author

Modified Delphi panel consensus recommendations for management of severe aplastic anemia.

Blood advances·2024

Same author

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

The New England journal of medicine·2024

Same author

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.

The Lancet. Haematology·2022

Same author

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Journal of the National Comprehensive Cancer Network : JNCCN·2022